NDC 0074-1824 - Novocain
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0074-1824
- Package NDCs from labels
- 0074-1824-30
- Manufacturer
- Hospira, Inc.
- Effective date
- 2007-04-16
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NOVOCAIN ® PROCAINE HYDROCHLORIDE INJECTION, USP | Hospira, Inc. | 2007-04-16 | Human prescription drug label |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0074-1824-30 | Novocain | 1 in 1 CARTON | INJECTION, SOLUTION | 1 | 1 | |
| 0074-1824-30 | Novocain | 100 in 1 CASE | INJECTION, SOLUTION | 100 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Procaine Hydrochloride | ACTIVE INGREDIENT | 95URV01IDQ | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Procaine | ACTIVE MOIETY | 4Z8Y51M438 | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Acetone Sodium Bisulfite | INACTIVE INGREDIENT | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | ||
| Chlorobutanol | INACTIVE INGREDIENT | HM4YQM8WRC | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Hydrochloric Acid | INACTIVE INGREDIENT | QTT17582CB | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Sodium Chloride | INACTIVE INGREDIENT | 451W47IQ8X | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | NOVOCAIN (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Amidate | ETOMIDATE | Hospira, Inc. | b7ed5bf8-ba75-44dc-8f81-96b4ad5766be | 2026-05-20 | Warnings, Adverse reactions | Hospira, Inc. |
| Hextend | HETASTARCH | Hospira, Inc. | fc79700c-6c3b-4998-8307-4dc8c81c5041 | 2026-05-20 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Metoclopramide | METOCLOPRAMIDE | Hospira, Inc. | 146803a1-199d-4789-b128-e974bdd03322 | 2026-05-20 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Chloride | SODIUM CHLORIDE | Hospira, Inc. | a2a964f7-c3ec-4dfb-e3a0-6d8136a80397 | 2026-05-19 | Warnings, Adverse reactions | Sodium Chloride Hospira, Inc. |
| Atropine Sulfate | ATROPINE SULFATE | Hospira, Inc. | ad8916e7-206e-409e-2582-30d072845dd4 | 2026-05-18 | Warnings, Adverse reactions | Hospira, Inc. |
| COPPER | CUPRIC CHLORIDE | Hospira, Inc. | a84d61a4-8e7f-4be1-aba6-f633b334aafc | 2026-05-18 | Warnings, Adverse reactions | Hospira, Inc. |
| Pamidronate Disodium | PAMIDRONATE DISODIUM | Hospira, Inc. | 9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23 | 2026-05-14 | Warnings, Adverse reactions | Hospira, Inc. |
| DOPamine Hydrochloride | DOPAMINE HYDROCHLORIDE | Hospira, Inc. | 1f306ad2-3606-4525-5a8a-ce78f426c1a2 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| Furosemide | FUROSEMIDE | Hospira, Inc. | 39fd32f2-6bb7-4a65-d298-e48d26bc80c7 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| FUROSEMIDE | FUROSEMIDE | Hospira, Inc. | aaced7a8-c3d7-4d66-8c07-aa407b8b3f35 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| ZINC | ZINC CHLORIDE | Hospira, Inc. | 9a1914a0-e195-4233-c1be-bc2075580eb8 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| Dopamine Hydrochloride in Dextrose | DOPAMINE HYDROCHLORIDE IN DEXTROSE | Hospira, Inc. | 08f23f6e-150d-45ea-098e-f2edf64c21a1 | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Ketamine Hydrochloride | KETAMINE HYDROCHLORIDE | Hospira, Inc. | bb912318-2e22-4469-b0a2-774803ee1bb8 | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Heparin Sodium | HEPARIN SODIUM | Hospira, Inc. | 0413f511-6b34-4c15-e48b-3fad08baacbe | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Heparin Sodium | HEPARIN SODIUM | Hospira, Inc. | 32e34077-aff1-4ec7-f9b0-b8e240768fb8 | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Phosphates | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE AND SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | Hospira, Inc. | 6f044d16-295e-43ff-72a3-b045c387bc5c | 2026-05-11 | Warnings, Adverse reactions | Hospira, Inc. |
| Daptomycin | DAPTOMYCIN | Hospira, Inc. | 1957b6ce-7382-4a7b-bf02-3595948d09c6 | 2026-05-08 | Warnings, Adverse reactions | Hospira, Inc. |
| Sterile Water | WATER | Hospira, Inc. | 3a6422e1-feee-4095-8883-2b0837039e6e | 2026-05-07 | Warnings, Adverse reactions | Hospira, Inc. |
| Metoprolol Tartrate | METOPROLOL TARTRATE | Hospira, Inc. | f65e93ec-4db6-44fa-bff1-8ae89aa8243f | 2026-05-04 | Warnings, Adverse reactions | Hospira, Inc. |
| TAZICEF | CEFTAZIDIME | Hospira, Inc. | 40d48c5d-650e-461b-a67b-7e65772d1b92 | 2026-05-04 | Warnings, Adverse reactions | Hospira, Inc. |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.